Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Lifecore Biomedical Inc.(LFCR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LFCR
10/23/2026: LFCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Lifecore Biomedical is a specialized contract development and manufacturing organization focusing on sterile injectable drug services for the pharmaceutical and biotech industries. Its main strengths lie in its technical expertise in complex, high-value formulations, positioning it well in the growing biologics market. The primary investment story centers on the company’s recent transformation into a pure-play CDMO, with significant opportunity for growth as it scales operations. However, investors must weigh this against substantial execution, competitive, and regulatory risks, alongside the company’s limited scale. The stock may best suit growth-oriented investors who can tolerate volatility and should monitor developments in facility utilization and major client contract wins.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through the CDMO market expansion but faces execution risks regarding its strategic scale-up. |
| Momentum investor | Weak fit | The stock has not consistently displayed the strong price momentum required for this style, pending clearer signs of operational breakout. |
| Value investor | Mixed fit | Valuation is sensitive to the success of the ongoing transition, requiring a nuanced view of potential future earnings power. |
| Dividend investor | Weak fit | The company does not pay dividends and is currently in a capital-intensive growth phase. |
| Low-risk investor | Weak fit | Small-cap volatility and the inherent risks of a company in transition make this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a small-cap company in a transition phase, the stock is subject to significant price swings. |
| Valuation risk | Medium / high | Future value is highly dependent on achieving targeted utilization rates and operating efficiencies. |
| Competition risk (CDMO giants) | High | The company must compete against established global players with far greater resources and manufacturing footprints. |
| Business quality | Medium | While technical expertise is high, the business is still stabilizing after a major structural pivot. |
| Dividend income | Low / none | Income-focused investors will not find yield here as capital is reinvested into operations. |
| Execution risk | High | Successfully managing complex drug manufacturing to meet client and regulatory requirements is essential for long-term viability. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -52.17% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.60M USD | Price to earnings Ratio - | 1Y Target Price 6.28 |
Price to earnings Ratio - | 1Y Target Price 6.28 | ||
Volume (30-day avg) 573.5K shares | Beta 0.98 | 52 Weeks Range 3.63 - 8.98 | Updated Date 10/25/2026 |
52 Weeks Range 3.63 - 8.98 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Sterile Fill-Finish | Revenue generated from long-term contracts to manufacture sterile injectables for pharma/biotech clients. | The company acts as a manufacturer for other companies' drugs, earning fees for producing high-quality, sterile injectable products. |
Valuation
Trailing PE - | Forward PE 8.67 | Enterprise Value 307.79M | Price to Sales(TTM) 1.87 |
Enterprise Value 307.79M | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 2.39 | Enterprise Value to EBITDA 8.11 | Shares Outstanding 37.91M | Shares Floating 19.34M |
Shares Outstanding 37.91M | Shares Floating 19.34M | ||
Percent Insiders 3.04 | Percent Institutions 72.49 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.